Metastatic non-muscle invasive bladder cancer with meningeal carcinomatosis: case report of an unexpected response

Teyssonneau, Diego; Daste, Amaury; Denis, Vincent; Hoepffner, Jean-Luc; Ravaud, Alain; Gross‐Goupil, Marine

doi:10.1186/s12885-017-3309-2

Cited by 14 publications

(6 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Even in non-muscle-invasive bladder cancer, a case of MC with multiple bone metastases following transurethral resection with intravesical Bacillus Calmette-Guerin instillation was reported (case no. 32, Table I) (27). MC had already developed at initial diagnosis of bladder cancer in 4 cases (16.7%).…”

Section: Discussionmentioning

confidence: 95%

Meningeal carcinomatosis from bladder cancer: A case report and review of the literature

et al. 2019

View full text Add to dashboard Cite

A 66-year-old Japanese male patient was referred to Saitama Medical University International Medical Center for treatment of bladder cancer (clinical stage T2 or higher without metastasis), and underwent radical cystectomy with pelvic lymphadenectomy. The histopathological diagnosis was high-grade urothelial carcinoma (pathological stage T2bN2, ly1, v0) and 2 cycles of adjuvant systemic chemotherapy (gemcitabine plus cisplatin) were administered. At 15 months after the operation, mediastinal and lung hilar lymph nodes and multiple bone metastases were identified on computed tomography imaging. After 3 cycles of the previous regimen as salvage systemic chemotherapy, the lymph node metastases had shrunk and the bone metastases were stable; therefore, further chemotherapy was planned. At 26 days after the initiation of the 4th cycle, the patient felt nausea and lower limb weakness. Spinal and brain magnetic resonance imaging with contrast medium revealed diffuse enhancement at the surface of the spinal cord and brain. In addition, abnormal signal intensity in the subarachnoid space was observed on fluid-attenuated inversion recovery imaging; therefore, the patient was diagnosed with meningeal carcinomatosis (MC). Treatment, including whole-brain radiotherapy, was planned for MC; however, the patient's condition rapidly worsened and he succumbed to the disease 14 days after the diagnosis of MC. The definitive diagnosis of MC was confirmed at autopsy.

show abstract

Section: Discussionmentioning

confidence: 95%

Meningeal carcinomatosis from bladder cancer: A case report and review of the literature

et al. 2019

View full text Add to dashboard Cite

show abstract

“…At least 2 cases of distant bone metastasis in non–muscle invasive disease have been reported in the literature. 4 , 18 In one case, a patient with stage T1HG showed no evidence of lymphovascular invasion or muscle invasive disease at the initial TURBT or the subsequent restaging TURBT. 18 As the patient’s primary tumor location made complete resection difficult, a partial cystectomy was performed, and lymphadenectomy at that time showed no evidence of regional metastasis.…”

Section: Discussionmentioning

confidence: 99%

“…The most common reported sites of metastasis for UC are liver (47%), lung (45%), or bone (32%). 4 While bone may be a frequent site of metastasis, the bones of the skull are infrequently involved. We report here the 13th known case of UC metastatic to the jaw.…”

Section: Discussionmentioning

confidence: 99%

Non–Muscle Invasive Papillary Urothelial Carcinoma Metastatic to the Mandible

Frydenlund

Zakharia

Garje

et al. 2018

Journal of Investigative Medicine High Impact Case Reports

View full text Add to dashboard Cite

Urothelial carcinoma, the most common histologic subtype of bladder cancer in the United States, most frequently presents as non–muscle invasive disease. Initially, therapy involves transurethral endoscopic resection and subsequent intravesical therapies with extended surveillance for high-risk disease. Even with the best treatments, recurrence and progression can occur. However, metastasis of non–muscle invasive bladder cancer to distant sites without evidence of progression or regional metastasis is rare. In this article, we present the case of a patient with high-grade papillary urothelial carcinoma who developed an unusual metastasis to the mandible, confirmed by GATA-3 immunostaining, over 4 years after initial transurethral resection. Prior to the development of metastatic disease, this patient had no evidence of local recurrence during maintenance Bacillus Calmette-Guerin intravesical therapy and concurrent surveillance. Positron emission tomography-computed tomography taken after presentation with mandibular metastasis did not show any evidence of regional metastasis. This case highlights an unusual location for distant metastasis of urothelial carcinoma occurring in a patient without evidence of muscle invasive disease or regional metastasis. We additionally highlight the utility of GATA-3 immunostaining in identifying urothelial carcinoma histologically.

show abstract

“…In the treatment of NB, cisplatin, as a frontline chemotherapy agent, which can deliver damage to DNA, often fails to exert tumor-suppressing effects, as a result of a decreased sensitivity of the tumor cells [42]. Studies have shown that GATA3 is associated with cisplatin chemoresistance in high-grade serous ovarian carcinoma [17] and nonmuscle invasive urothelial carcinoma [43]. In agreement with the role of GATA3 to support cisplatin chemoresistance in high-grade serous ovarian carcinoma, our study confirmed that GATA3 expression was negatively correlated with the sensitivity of CHP-212 cells and SK-N-AS cells to cisplatin, suggesting that GATA3 confers cisplatin chemoresistance on NB cells.…”

Section: Discussionmentioning

confidence: 99%

GATA3 positively regulates PAR1 to facilitate in vitro disease progression and decrease cisplatin sensitivity in neuroblastoma via inhibiting the hippo pathway

Wang¹,

Dai²,

Zhang³

2022

Anti-Cancer Drugs

View full text Add to dashboard Cite

GATA binding protein 3 (GATA3) is reported to critically involved in the pathogenesis of neuroblastoma (NB). This study investigated the specific role and mechanism of GATA3 in NB progression. JASPAR was utilized to predict GATA3’s downstream targets, whose binding relation with GATA3 was inspected by a dual-luciferase reporter assay. NB cell lines underwent transfection of GATA3/protease-activated receptor 1 (PAR1) overexpression plasmids or shGATA3, followed by cisplatin treatment. NB cell sensitivity to cisplatin, viability, migration, invasion, cell cycle progression and apoptosis were evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, wound healing assay, transwell assay and flow cytometry, respectively. Expressions of GATA3, PAR1, epithelial-mesenchymal transition-related molecules (N-Cadherin and Vimentin), hippo pathway-related molecules (mammalian Ste20-like kinase (Mst)1, Mst2, Mps one binding (Mob) 1, phosphorylated (p)-Mob1, Yes-associated protein (YAP) and p-YAP) in NB tissues and cell lines were assessed by western blot or qRT-PCR. GATA3 expression was increased in NB tissues and cells. GATA3 overexpression increased NB cell viability, promoted migration, invasion, and cell cycle progression, increased the expressions of N-Cadherin, Vimentin and YAP, decreased the expressions of Mst1, Mst2, Mob1, p-Mob1, p-YAP and the ratio of p-YAP to YAP, and attenuated cisplatin-induce cell apoptosis, which GATA3 knockdown induced the opposite effect. GATA3 directly targeted PAR1, whose overexpression increased NB cell viability, inhibited the hippo pathway, and attenuated cisplatin-induce cell apoptosis, and reversed GATA3 knockdown-induced effect on these aspects. GATA3 positively regulates PAR1 to facilitate in-vitro disease progression and decrease cisplatin sensitivity in NB via inhibiting the hippo pathway.

show abstract

Metastatic non-muscle invasive bladder cancer with meningeal carcinomatosis: case report of an unexpected response

Cited by 14 publications

References 14 publications

Meningeal carcinomatosis from bladder cancer: A case report and review of the literature

Meningeal carcinomatosis from bladder cancer: A case report and review of the literature

Non–Muscle Invasive Papillary Urothelial Carcinoma Metastatic to the Mandible

GATA3 positively regulates PAR1 to facilitate in vitro disease progression and decrease cisplatin sensitivity in neuroblastoma via inhibiting the hippo pathway

Contact Info

Product

Resources

About